PSTi8 Pancreastatin Inhibitor Peptide

PEGKGEQEHSQQKEEEEEMAV-NH2 is PSTi8, a C-terminally truncated synthetic peptide derived from human pancreastatin. PSTi8 was developed as an antagonist/inhibitory peptide for pancreastatin-associated metabolic effects. Peer-reviewed studies using this exact amidated sequence report improved insulin sensitivity and glucose homeostasis in experimental models and describe inhibition of pancreastatin-associated effects on glucose uptake, hepatic glucose production and inflammatory signaling.

• pancreastatin inhibition studies
• insulin-resistance research
• glucose-homeostasis studies
• metabolic and inflammatory signaling research

PSTi8 is a synthetic pancreastatin-derived research peptide rather than an endogenous full-length hormone. Reported metabolic effects are based primarily on cellular and animal models and should not be generalized to clinical efficacy.

1. Discovery of pancreastatin inhibitor PSTi8 for the treatment of insulin resistance and diabetes: studies in rodent models of diabetes mellitus
2. The immunomodulatory functions of chromogranin A-derived peptide pancreastatin
3. Pancreastatin inhibitor PSTi8 ameliorates streptozotocin-induced diabetes by suppressing hepatic glucose production